Yazen uses acquisitions to accelerate market entry

This acquisition matters because in European telehealth, buying a local operator can be faster than building one country from zero. Yazen already had the obesity treatment playbook, the app workflow, and clinical protocols, but each market still needs local doctors, operating entities, and country specific regulatory setup. Medstart gave Yazen an immediate base in Denmark, and Yazen used the same deal to expand its GLP-1 obesity offer in Norway, turning M&A into a shortcut for market launch, not just a way to add revenue.

• Yazen went from three core countries in 2023 to seven markets by 2025, showing that geographic rollout is central to the business. In that context, Medstart looks less like a one off tuck in and more like a repeatable entry method for Europe’s still fragmented telehealth markets.
  1 sacra 2 yazen
• The hard part in Europe is local complexity. Kry’s expansion shows why. Reimbursement, public system rules, and care delivery vary country by country, and Kry used acquisition in the UK to gain local distribution software and relationships. Yazen is applying the same logic on a smaller, obesity focused scale.
  6 sacra 7 sacra 8 pemcf
• This playbook is now common across weight care telehealth. Hims & Hers bought ZAVA in June 2025, then said the deal gave it immediate entry into Germany, France, and Ireland, plus an existing patient base. The lesson is that local licenses, operations, and customer trust can be more valuable than code.
  9 hims 10 sec 11 cnbc

The next leg of growth is likely to come from repeating this pattern in larger white space markets like France, Italy, and Central and Eastern Europe. If Yazen keeps buying local operators that already have clinicians, approvals, and patient acquisition channels in place, it can spread one core obesity care system across Europe much faster than country by country greenfield launches.